CRDF
Cardiff Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.39
+6.92%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.14
- Revenue estimate
- $81.5K
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.14
- EPS estimate
- -$0.12
- Revenue actual
- $104.0K
- Revenue estimate
- $63.7K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -0.4%
- Revenue beats (12Q)
- 11
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $9.00
- PT range
- $9.00 – $9.00
- Analysts
- 2
1 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.12 | -$0.14 | Miss -17.03% | $104.0K |
| May 14, 2026 | -$0.13 | -$0.18 | Miss -38.46% | $41.0K |
| Feb 25, 2026 | -$0.18 | -$0.11 | Beat 38.89% | $109.0K |
| Nov 6, 2025 | -$0.20 | -$0.17 | Beat 15.00% | $120.0K |
| Jul 29, 2025 | -$0.19 | -$0.21 | Miss -10.53% | $121.0K |
| May 8, 2025 | -$0.19 | -$0.20 | Miss -5.26% | $109.0K |
| Feb 27, 2025 | -$0.26 | -$0.21 | Beat 19.23% | $151.0K |
| Nov 7, 2024 | -$0.27 | -$0.25 | Beat 7.41% | $165.0K |
| Aug 8, 2024 | -$0.25 | -$0.26 | Miss -4.00% | $163.0K |
| May 2, 2024 | -$0.25 | -$0.22 | Beat 12.00% | $205.0K |
| Feb 29, 2024 | -$0.26 | -$0.21 | Beat 19.23% | $156.0K |
| Nov 2, 2023 | -$0.29 | -$0.22 | Beat 24.14% | $141.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026